Reagents and instruments for immunology, cell biology and molecular biology.

SARS-CoV-2 Spike (S1) (COVID-19)

Print

Cat# 544070-100ug

Size : 100ug

Brand : US Biological

544070 SARS-CoV-2 Spike (S1) (COVID-19)

Clone Type

Polyclonal

Host

human

Source

human

Swiss Prot

P59594

Isotype

IgG1,k

Grade

Affinity Purified

Applications

E N

Crossreactivity

Shipping Temp

Blue Ice

Storage Temp

-20°C

Recombinant monoclonal antibody to SARS-CoV-2 Spike with variable regions (i.e., specificity) from the B-cell clone CR3022. Manufactured using a proprietary recombinant platform technology. ||On 31 December 2019, the World Health Organization (WHO) was alerted of an outbreak of pneumonia in Wuhan City, China, caused by an unknown virus. The virus was sequenced and identified as a novel strain of Coronavirus one week later on 7 January 2020. It belongs to the same family of viruses which include Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS). 2019-nCoV is a positive-sense, single-stranded RNA virus which is thought to be of zoonotic origin. Symptoms of those infected include fever, dry cough, fatigue, shortness of breath and respiratory distress. Additionally, cases have resulted in renal failure, pneumonia and death. Those most seriously affected are individuals with already impaired immune systems, however approximately one quarter of otherwise well patients have required intensive care upon hospital admission.|Human-to-human transmission of the virus has been confirmed, with previous Coronavirus outbreaks (such as SARS) originating from similar environments in Asian markets, where humans and live animals are in close proximity.||Applications: |Suitable for use in Surface Plasmon Resonance (SPR), Crystallography, Neutralization and ELISA. Other applications not tested.||Recommended Dilution:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications

Product Type: Mab|Isotype: IgG1,k|Clone No: CR3022 (recomb)|Host: human|Source: human|Concentration: ~1mg/ml|Form: Supplied as a liquid in PBS, 0.02% Proclin 300.|Purity: Purified by Protein A affinity chromotography from culture supernatant.|Immunogen: Peripheral blood lymphocytes of a patient exposed to the SARS-CoV.|Specificity: Recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein. Also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020).||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

Immunogen

Peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Form

Supplied as a liquid in PBS, 0.02% Proclin 300.

Purity

Purified by Protein A affinity chromotography from culture supernatant.

Specificity

Recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein. Also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020).

References

1. Joyce GM, et al. (2020). A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. BioRxiv.|2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199–1207.|3. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020;AAC.00483-20.|4. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574.|5. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237.|6. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385.|7. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20.|8. Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;eabb7269.|9. Zhao et al. (2020). Single -cell RNA 2expression profiling of ACE2, the putative receptor of Wuhan 2019 -nCov. BioRxiv.|10. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.